Table 1.
Patients’ characteristics and treatment modalities
| Variable | ||
|---|---|---|
| Age | Median (range) | 57.0 (34.3–79.9) |
| Body mass index (BMI) | Median (range) t0 a | 25.0 (18.7–63.5) |
| Median (range) t1 a | 25.5 (16.4–65.3) | |
| pT stage | Number of patients (%) | |
| I | 97 (48.5%) | |
| II | 95 (47.5%) | |
| III | 4 (2.0%) | |
| IV | 3 (1.5%) | |
| pN stage | ||
| 1 | 165 (82.5%) | |
| 2 | 28 (14.0%) | |
| 3 | 7 (3.5%) | |
| Grading | ||
| 1 | 13 (6.5%) | |
| 2 | 144 (57.0%) | |
| 3 | 69 (34.5%) | |
| Tumor size (mm) | Median (range) | 19 (0–90) |
| Resection volume (g) | Median (range) | 50 (5–931) |
| Resected lymph nodes (n) | Median (range) | 17.5 (2–55) |
| Involved lymph nodes (n) | Median (range) | 2 (0–22) |
| Hormone therapy | Number of patients (%) | |
| Yes | 152 (76.0%) | |
| No | 43 (21.5%) | |
| Chemotherapy | Total | |
| yes | 156 (78.0%) | |
| no | 44 (22.0%) | |
| Adjuvant | ||
| Yes | 133 (66.5%) | |
| No | 67 (33.5%) | |
| Neoadjuvant | ||
| Yes | 23 (11.5%) | |
| No | 177 (88.5%) | |
| Radiation volume | Breast | |
| yes | 200 (100%) | |
| SCRT | ||
| Yes | 75 (37.5%) | |
| No | 125 (62.5%) | |
| Boost (breast) | ||
| Yes | 65 (32.5%) | |
| No | 135 (67.5%) | |
| Follow up (years) | Median (range) | 10.1 (4.9–15.9) |
at0 = at time of irradiation; t1 = at time of survey